20 annual accounts with figures on one time axis, 26 filings since 2000
peak of €120,307 in 2008
€118,424▲ 51.4%
lowest -€16,315 in 2022
€81,829▲ 99.1%
peak of €447,235 in 2025
€447,235▲ 22.4%
€92,682▲ 42.6%
peak of 0.9 FTE in 2007
0 FTE
Board1 name since 1999
1 directorHidden nameVisible after signing in
Documentsfilings and deeds
31-08-202631 days late
2025abbreviated format
Gross margin from €78,214 to €118,424Result from €41,110 to €81,829Equity from €365,406 to €447,235Debts from €64,987 to €92,682Cash from €48,521 to €93,542
Higher solvency than 91% of companies in retail trade. The sector median is 36.8%, over 13,303 companies.
Checked score
Checked score
The higher the Checked score (0 to 100), the smaller the chance that the company goes bankrupt within twelve months. That chance sets the band, from Critical to Excellent, and within the band how the company does against its sector peers counts too. With a low score, agree a shorter payment term, an advance or security.
XXVisible after signing in
HiddenVisible after signing in
Bankruptcy probability within 12 months
Bankruptcy probability
It is the chance that the company goes bankrupt within twelve months, estimated from the registers, the annual accounts and the Belgian Official Gazette. At 0.2%, about 2 in 1,000 comparable companies go bankrupt. The higher it is, the shorter the payment term to agree.
XXVisible after signing in
Financial strength
Financial strength
Financial strength measures the balance sheet and the results with three figures out of 100 from the latest annual accounts: solvency, liquidity and profitability. It does not directly set the Checked score's band. How the company does against its sector peers on these and on growth does count for its place within the band.
XXVisible after signing in
XXVisible after signing in
XXVisible after signing in
Score breakdown
Visible after signing inVisible after signing in
Comparable companies, two years later
In July 2024, 20,149 companies had the same profile as APOTHEEK VERMASSEN has now. Each dot stands for 51 companies, two years later.
95.0%
were still trading
4.7%
stopped another way
0.2%
went bankrupt
Small
20 years or older
solvency 30% or more
a profit of 5% of the balance sheet or more
Test of the method
The method was tested on the 497,994 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
The companies in ten equal groups, from the lowest to the highest expected share
Group
Expected
Actual
1
0.2%
0.2%
2
0.3%
0.5%
3
0.5%
0.6%
4
0.7%
0.8%
5
0.9%
0.9%
6
1.3%
1.5%
7
1.6%
1.8%
8
1.8%
1.8%
9
2.9%
3.1%
10
5.6%
6.1%
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 20,149 companies, not a prediction for APOTHEEK VERMASSEN. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit verdict
The credit verdict says how much credit you can give the company on open account. “Acceptable” means normal terms, “With conditions” means limiting the amount or the term. “Not advised” means asking for payment up front.
Visible after signing inVisible after signing in
Credit check for an amount and term of your choice
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0466544066
Name after signing inVisible after signing in (statutory director) and Name hiddenVisible after signing in (statutory director) appointed
General meeting of 22-08-2022 · Gazette deed
Capital decrease of €153,000 to €18,600
The capital fell from €171,600 to €18,600 · General meeting of 27-11-2018 · Gazette deed
Capital increase of €153,000 to €171,600
After the increase, the capital stands at €171,600 · General meeting of 30-12-2013 · Gazette deed
Sector peers are the companies with the same activity (NACE code) and, where stated, the same size, that the company is compared with. A percentile says how many of them do worse.
These companies have the same main activity as APOTHEEK VERMASSEN: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €526,000 and €764,000, founded between 1990 and 2005.
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of APOTHEEK VERMASSEN?
APOTHEEK VERMASSEN is a private limited company (BV).
When was APOTHEEK VERMASSEN founded?
APOTHEEK VERMASSEN was founded on 14-07-1999.
Is APOTHEEK VERMASSEN still active?
Yes, APOTHEEK VERMASSEN is an active enterprise in the KBO register.
What is the turnover of APOTHEEK VERMASSEN?
The turnover in financial year 2025 is about €560,000. This figure is estimated from the gross margin of €118,424 and 43 comparable companies (NACE 477). It probably lies between €360,000 and €1.2m.Financials
Is APOTHEEK VERMASSEN profitable?
In financial year 2025, APOTHEEK VERMASSEN made a profit of €81,829.
Where can I find the annual accounts of APOTHEEK VERMASSEN?
APOTHEEK VERMASSEN filed 26 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of APOTHEEK VERMASSEN due?
APOTHEEK VERMASSEN must file the annual accounts for financial year 2026 by 31-07-2027.Timeline